QLGN תחזית צמיחת רווח נקי למניה לשנה הבאה Qualigen Therapeutics, Inc.

A critical reliance on external R&D contractors has created significant vulnerability for Qualigen Therapeutics (QLGN). The forward earnings per share trend visualizes this risk, where 0.00 captures the current value of the indicator. Despite the defensive qualities of the diagnostics sector, the company has pivoted toward aggressive restructuring and a strategic shift toward oncology to preserve capital and facilitate a potential merger.

A conservative investor assesses the fundamental stability of Qualigen Therapeutics (QLGN) through the dynamics of expected earnings per share. This calculation is based on the analyst consensus for future cash flows; therefore, the EPS growth prospects for the next fiscal year reflect the probability of commercializing oncology drugs and the stability of revenues from diagnostic tests, determining the risk of capital freeze in a volatile biopharmaceutical asset.